Study summary
HER2-targeted antibody plus chemotherapy shrank 60% of HER2-positive salivary cancers
60.0%response rate
What was tested
Trastuzumab with docetaxel chemotherapy for recurrent or metastatic HER2-positive salivary gland cancer.
What they found
- Response rate was 60.0%, with disease control in 93.3%.
- Median overall survival was 33.8 months.
- Low white cell counts were universal.
What it means
Led to approval of trastuzumab for HER2-positive salivary cancer in Japan.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.